The Role of Resolvin D1 in the Differential Diagnosis of the Cholangiocarcinoma and Benign Biliary Diseases

Basit Öğe Kaydı
dc.contributor.authorGül-Utku, Özlem
dc.contributor.authorKaratay, Eylem
dc.contributor.authorErgül, Bilal
dc.contributor.authorKısa, Üçler
dc.contributor.authorErdin, Züleyha
dc.contributor.authorOğuz, Dilek
dc.date.accessioned2021-01-14T18:11:02Z
dc.date.available2021-01-14T18:11:02Z
dc.date.issued2020
dc.departmentKKÜ
dc.description.abstractBackground: The discrimination of malignant biliary strictures from benign biliary diseases (BBDs) is challenging and complicated. We aimed to investigate whether Resolvin D1 (RvD1) would aid in the discrimination of cholangiocarcinoma (CCA) from BBDs. Methods: Thirty-one patients with CCA, 27 patients with BBD, and 30 healthy controls were enrolled in this crosssectional study. The diagnosis of CCA was based on results obtained from abdominal USG, MRCP, abdominal CT, endosonography, and tumor markers, including CEA and CA 19-9. Histopathological evaluation was performed in the majority of patients, and the final diagnosis was based on surgery or biopsy results. RvD1, CEA, and CA 19-9 were analyzed in all patients with CCA and BBD. Results: RvD1 was significantly lower in those with CCA compared to patients with BBD and healthy controls. In addition, CEA and Ca 19-9 levels were significantly higher in the CCA group than the BBD group (p < 0.001). RvD1 concentration, CA 19-9 concentration, and total bilirubin level were found to be correlated with tumor stage (r = -0.702, 0.390, and 0.569, respectively). ROC curve analysis revealed that an RvD1 concentration of < 380 ng/mL (AUC: 0.783, 95% CI: 0673 - 0.893, p < 0.001) and CA 19-9 concentration of > 94.5 U/mL (AUC: 0.94, 95% CI: 0.898 - 0.998, p < 0.001) could be used to discriminate patients with CCA from those with BBD. Conclusions: Resolvin D1 and CA 19-9 levels might be used to effectively discriminate between BBD and CCA. Moreover, both RvD1 and CA 19-9 levels are associated with the stage of CCA, indicating that they may also be used in assessing disease progression.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.7754/Clin.Lab.2020.200212
dc.identifier.endpage917en_US
dc.identifier.issn1433-6510
dc.identifier.issue5en_US
dc.identifier.pmid32390401
dc.identifier.scopus2-s2.0-85084395529
dc.identifier.scopusqualityQ3
dc.identifier.startpage911en_US
dc.identifier.urihttps://doi.org/10.7754/Clin.Lab.2020.200212
dc.identifier.urihttps://hdl.handle.net/20.500.12587/12862
dc.identifier.volume66en_US
dc.identifier.wosWOS:000545456000025
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCLIN LAB PUBLen_US
dc.relation.ispartofCLINICAL LABORATORY
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbenign biliary diseaseen_US
dc.subjectbiliary obstructionen_US
dc.subjectCA 19-9en_US
dc.subjectcholangiocarcinomaen_US
dc.subjectRvD1en_US
dc.titleThe Role of Resolvin D1 in the Differential Diagnosis of the Cholangiocarcinoma and Benign Biliary Diseasesen_US
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu